NASDAQ:DARA - DARA Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$0.29
Today's RangeN/A
52-Week Range$0.67 - $1.05
VolumeN/A
Average Volume118,843 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company's primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

Receive DARA News and Ratings via Email

Sign-up to receive the latest news and ratings for DARA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:DARA
CUSIPN/A
Phone+1-816-9147027

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

DARA Biosciences (NASDAQ:DARA) Frequently Asked Questions

What is DARA Biosciences' stock symbol?

DARA Biosciences trades on the NASDAQ under the ticker symbol "DARA."

How were DARA Biosciences' earnings last quarter?

DARA Biosciences Inc (NASDAQ:DARA) announced its earnings results on Monday, November, 2nd. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.14). The specialty pharmaceutical company earned $1.18 million during the quarter, compared to analysts' expectations of $0.83 million. View DARA Biosciences' Earnings History.

Has DARA Biosciences been receiving favorable news coverage?

News headlines about DARA stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. DARA Biosciences earned a news impact score of -2.0 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term.

What other stocks do shareholders of DARA Biosciences own?

How do I buy shares of DARA Biosciences?

Shares of DARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DARA Biosciences' official website?

The official website for DARA Biosciences is http://www.darabiosciences.com/.

How can I contact DARA Biosciences?

DARA Biosciences' mailing address is 8601 Six Forks Rd Ste 160, RALEIGH, NC 27615-2965, United States. The specialty pharmaceutical company can be reached via phone at +1-816-9147027.


MarketBeat Community Rating for DARA Biosciences (NASDAQ DARA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  162
MarketBeat's community ratings are surveys of what our community members think about DARA Biosciences and other stocks. Vote "Outperform" if you believe DARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel